Company / Return on Equity (ROE)
Beam Therapeutics Inc. Return on Equity (ROE) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-6.5%
FY2025
5-year range
-51.4% / -6.5%
FY2021-FY2025
Trend
+87.4%
vs FY2024
Sector context
#56 of 190
Health Care
What the data says
Beam Therapeutics Inc. reports negative total equity of -6.5% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-6.5% in FY2025 with a 3-year CAGR of +33.0%.
Improved from -13.5% to -6.5% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +33.0pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#56 of 190 in Health CareTop 29% of 190This company -6.5% Sector average -50.3%
▼
+87.2% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 87.4% year-over-year.
- Currently 43.9pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 1.06 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -6.5% | +87.4% |
| FY2024 | -51.4% | -280.4% |
| FY2023 | -13.5% | +65.7% |
| FY2022 | -39.4% | +12.1% |
| FY2021 | -44.8% | - |
| FY2020 | - | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026